About macular disease
AMD overview
What is AMD?
Stages of AMD
Risk factors for AMD
How do you know if you have AMD?
Detecting & monitoring changes in vision
Diagnosing AMD
Eating for eye health
Supplements for AMD
AMD treatment
AMD FAQ
AMD video series
About diabetic retinopathy
Reducing the risk of diabetic retinopathy
Other risk factors
Diagnosing diabetic eye disease
Symptoms of diabetic retinopathy
Treatment for diabetic retinopathy
Diabetic eye disease FAQs
Diabetic eye disease video series
Other macular diseases
Vitelliform macular dystrophy and Best disease
Macular telangiectasia
Myopic macular degeneration
Retinal vein occlusion
Vitreomacular traction syndrome
Support services overview
Check My Macula
Understanding government services
Government services overview
Understanding My Aged Care
Blind pensions
Understanding NDIS
Understanding low vision services
Understanding the eye health profession
Nutrition and lifestyle
Psychological and emotional needs
Nutrition and lifestyle video series
Living with vision loss
Vision loss overview
Vision loss, low vision and legal blindness
Low vision assessment
Moving forward with vision loss
Vision loss tips
Low vision aids and technology
Charles Bonnet syndrome
Living with vision loss video series
What is a carer?
Impact on carers
Caring for the carer
Developing a care plan
Cost of macular disease treatment
Macular disease drug costs
Medicare items for macular disease
Medicare benefits
Other rebates
Understanding research
MDFA-funded research
MDFA Research Grants
Grant Family Fund
Register an interest
Key research publications
About MDFA
A champion for macular disease
State patrons
Your donation
Visionary Partners and bequests
Refer to us
Eye health video series
Stargardt disease is also called Stargardt dystrophy or fundus flavimaculatus.
What is Stargardt disease?
Stargardt disease, also called Stargardt dystrophy or fundus flavimaculatus, is a genetic eye disease. It is the most common childhood macular condition.
The disease is caused by more than 1,000 different types of mutations in a single gene.
Stargardt disease affects about one in 10,000 people.
It usually first appears between the ages of 10 to 20, although you may not experience visual problems until the age of 30 to 40.
Stargardt disease causes parts of the macula (the central part of the retina) to stop working. It impacts detailed central vision and colour perception. In more severe cases, the disease may also affect side (peripheral) vision and night vision.
Learn more about how the eye works
Changes to the eye with Stargardt disease
In Stargardt disease, a waste product called lipofuscin slowly builds up in the retinal pigment epithelium (RPE), a special layer of the retina.
The cells of the RPE normally clear away waste products like lipofuscin. However, in someone with Stargardt disease, the faulty gene gives incorrect instructions. This prevents the removal of these waste products.
The waste products gradually build up, damaging the cells in the macula and sometimes in the rest of the retina.
There are two main findings in the retina of people with Stargardt disease.
First, there is often an oval-shaped area, often referred to as 'beaten bronze' in appearance, around the macula. This area tends to deteriorate over time and causes changes in the way the cells of the macula work. This leads to a loss of visual acuity, meaning vision becomes less sharp.
The second change involves yellowish flecks in the retina. Sometimes people have just these flecks without the macular lesion. These people used to be diagnosed with fundus flavimaculatus. However, some researchers believe the macular lesion and the yellow flecks are both caused by the same gene. This leads them to conclude they are different versions of the same genetic problem.
Effect on vision
Stargardt disease usually only affects the macula, so central vision is impacted.
At first, you may notice your central vision is unclear. Your vision also could be distorted or blurred.
As the disease progresses, you may notice a blank patch in the centre of your vision.
Stargardt disease doesn't usually affect peripheral vision. Since we use our peripheral vision when we are moving around, most people with Stargardt disease can manage to move about on their own, albeit with some difficulty.
Stargardt disease can also cause problems such as glare and you may have difficulties adapting to changing light conditions.
Watch: Alicia's story
The genetic cause of Stargardt disease
As mentioned above, Stargardt disease is caused by more than 1,000 different types of faults, or mutations, in a single gene. The first gene mutation responsible for Stargardt disease was discovered in 1997. Since then other gene mutations that can cause the disease have been discovered.
Genetic inheritance
Genes are the set of instructions on how our bodies should develop.
We all inherit two sets of genes, one set from each of our parents, and we each pass on one of those sets of genes to our children.
These sets of genes lie in pairs (one from each parent). These genes determine our traits – the many things that make us individuals, such as hair or eye colour, or whether we get certain genetic conditions. There are two ways a trait can be passed through genes to children – by a dominant pattern or a recessive pattern.
Dominant and recessive traits
A dominant trait only needs to be inherited from one parent. With this type of inheritance, only one copy of the gene is needed. When a dominant gene from one parent is paired with a recessive gene from the other parent, the dominant gene switches on the trait. It is dominant over the other (recessive) gene inherited from the other parent and the child will have that dominant trait.
With recessive traits, two copies of the gene are needed. This means both parents have to carry and pass on a copy of the recessive gene. When this happens, the recessive trait is switched on and the child will have that recessive trait.
How Stargardt disease fits these patterns
Stargardt disease is usually inherited in an autosomal recessive pattern. This means that when two carriers of this faulty gene have a child, there is a one in four (25 per cent) chance of the child having Stargardt disease.
If an individual with Stargardt disease has a child with a partner who is a carrier, the child would have a one in two – or 50 per cent – chance of having the disease.
The most common gene associated with Stargardt disease is called ABCA4. Recently, a rare dominant version of Stargardt disease has also been identified in the ELOVL4 gene. Genetic tests are available to determine which gene mutation is causing the disease.
Further information and genetic counselling is available from specialist clinics. Your ophthalmologist will be able to advise you about local genetic services. People with Stargardt disease may also wish to be entered onto the Australian Inherited Retinal Disease Register and DNA Bank. This facility is located at Sir Charles Gairdner Hospital in Perth.
Stargardt disease has characteristic changes in the macula that can be detected during an eye examination.
Your eye health professional may use a number of tests to diagnose and characterise Stargardt disease. These tests may include fundus autofluorescence (FAF), optical coherence tomography (OCT) and sometimes fluorescein angiography (FA). Occasionally, an electroretinogram (ERG) may be performed to help in the early diagnosis of Stargardt disease in children.
Your ophthalmologist may also recommend genetic testing to confirm diagnosis early, inform prognosis and your eligibility for therapies and trials. This will also help allow for low vision interventions, vocational and educational modifications and family planning.
There is currently no treatment for Stargardt disease itself. In rare cases, new, leaky blood vessels can form under the retina, leading to sudden and significant vision loss. This is called neovascularisation. Your ophthalmologist can treat neovascularisation with the use of injections into the eye of an anti-VEGF drug, usually with considerable success.
Researchers have reported that exposure to ultraviolet light may cause further retinal damage. Therefore, if you have Stargardt disease, wear sunglasses with UV protection that conforms to Australian standards. A hat with a wide brim can also protect you from the sun's damaging ultraviolet rays.
Some reports have noted dimming of vision in Stargardt patients while smoking, so it is recommended you don't smoke.
It's hard to stop but with help and support, you can quit.
Visit the Quit website
Proper nutrition will help support your macula. The recommended eye-healthy diet is:
eat fish two to three times a week, dark green leafy vegetables and fresh fruit daily, a handful of nuts a week, and limit your consumption of fats and oils
choose low glycemic index (GI) carbohydrates instead of high GI whenever possible
live a healthy lifestyle, control weight, and exercise regularly
In consultation with your doctor and eye health professional, a supplement containing lutein and zeaxanthin may also be considered.
In general, these are the same dietary recommendations that are made for age-related macular degeneration so our nutrition fact sheet may help.
AMD and nutrition fact sheet
There is no evidence that supplements based on the Age-Related Eye Disease Study (AREDS2), which are commonly recommended for age-related macular degeneration, are of any benefit for Stargardt disease.
Research has shown that supplements with excessive amounts of vitamin A should be avoided in Stargardt disease as gene mutations may lead to abnormal synthesis of the vitamin in the eye, resulting in increased loss of vision. So don't exceed the normal recommended dietary allowance of vitamin A.
Significant research is taking place in this area, with several new drug candidates showing promise. In particular, several new gene therapy treatments are being developed, which will hopefully enable the insertion of the correct genes to negate the effect of the faulty genes.
In addition, a substantial amount of research is taking place with stem cell therapy. Human stem cell studies with Stargardt disease have recently commenced. It is hoped that stem cell treatment may ultimately be able to replace damaged retinal cells.
Macular Disease Foundation Australia is the largest non-government source of grant funds into macular disease research in Australia.
Managing vision loss
Although the long-term progression of the disease is variable, unfortunately most people with Stargardt disease eventually develop very poor vision. However, Stargardt disease doesn't cause total or black blindness.
A key priority with reduced loss is maintaining quality of life and independence.
Read more about living well with macular disease
Get the fact sheet
The information on this page is available as a fact sheet to download.
Stargardt disease fact sheet
About diabetic macular oedema
Treatment for diabetic macular oedema
Posterior vitreous detachment (PVD) and floaters
Health professionals video series
Low vision aids and technology can help you maintain quality of life and independence.
© Macular Disease Foundation Australia
Your contact form has been successfully submitted.
We aim to respond to your request by the next business day. If you require assistance sooner, please call our National Helpline on 1800 111 709 (Monday - Friday 9-5pm AEST).
If your query is about an eye emergency - including sudden changes to your vision or eye pain - please contact your optometrist or ophthalmologist as soon as possible.
Unfortunately there are no matches for your search.
Please try another search term.
Your expression of interest in our research grants program has been submitted.
We will be in touch at the next stage of the process.
Thank you for referring your patient to MDFA for non-clinical support and macular disease information. We will make contact with them within five business days.
Thank you for subscribing to MDFA's newsletter/s.
You can opt-out at any time by contacting us on [email protected] or via our National Helpline: 1800 111 709.
Tell people about MDFA's newsletters:
Thank you for registering for this event.
Let people know you're attending:
The is for health professionals only. Please enter your organisation and practitioner type to subscribe. If you are not a health professional, please untick this newsletter to continue.